Atea Pharmaceuticals Presents Favorable AT-752 Phase 1 Data for Treatment of Dengue Fever at American Society of Tropical Medicine & Hygiene 2022 Annual Meeting
November 03, 2022 07:00 ET
|
Atea Pharmaceuticals, Inc.
Safety and pharmacokinetic data in healthy volunteers support ongoing clinical development AT-752 is a novel, orally administered, direct-acting antiviral in Phase 2 development with a Fast Track...
Atea Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call on November 7, 2022
October 31, 2022 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and...
Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to AT-752 for Treatment of Dengue
September 26, 2022 07:00 ET
|
Atea Pharmaceuticals, Inc.
Dengue is the most prevalent mosquito-borne viral disease; endemic to 100 countries worldwide, with more than half the world’s populations at-risk AT-752 is a novel, orally administered,...
Atea to Advance Global Phase 3 Registrational Study of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19
September 13, 2022 07:00 ET
|
Atea Pharmaceuticals, Inc.
Novel Phase 3 Trial Design to Evaluate Bemnifosbuvir as Monotherapy and Combination Antiviral Therapy for COVID-19 Trial to Focus on High-Risk Patients at Greatest Risk for Disease Progression ...
Atea Pharmaceuticals Announces Upcoming Investor Events
September 07, 2022 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Atea management will participate in...
Atea Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
August 08, 2022 16:05 ET
|
Atea Pharmaceuticals, Inc.
Advancing Bemnifosbuvir to Late-Stage Development for COVID-19 Following Meetings with U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Emergency Task Force New Data...
Atea Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call on August 8, 2022
August 01, 2022 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and...
Atea Pharmaceuticals Participates in the William Blair Biotech Focus Conference
July 11, 2022 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief...
Atea Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference
June 01, 2022 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief...
Atea Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
May 10, 2022 06:30 ET
|
Atea Pharmaceuticals, Inc.
New clinical results from MORNINGSKY trial shows 71% reduction in hospitalization (secondary endpoint) in broad patient population with COVID-19 treated with bemnifosbuvir (AT-527) versus placebo...